TrialAnnals of oncology : official journal of the European Society for Medical Oncology2016

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.

C Weinstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.